By A Mystery Man Writer
Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.
Cutaneous responses in HER2+ metastatic breast cancer: A retrospective case series of a Phase 1b study of Tucatinib, an Oral HER2-specific inhibitor in combination with Capecitabine and/or Trastuzumab in third-line or later
Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
A retrospective, multicenter study of the efficacy of lapatinib
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis, Systematic Reviews
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis, Systematic Reviews
ALTTO rash substudy CONSORT diagram. *Out of 6194 patients
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Frontiers Cutaneous manifestations associated with immune checkpoint inhibitors
PDF) Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical
Targeting HER2-positive breast cancer: advances and future
Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs